Fast Five Quiz: KRAS Mutations in Non-Small Cell Lung Cancer

Winston W. Tan, MD; Maurie Markman, MD


August 16, 2022

Lung cancer is the leading cause of cancer-related mortality worldwide, culminating in nearly 1.8 million deaths in 2020. Despite advances in detection and treatment, the 5-year survival rate for lung cancer is still below 20%. Non–small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, and lung adenocarcinoma is the most common histologic subtype. Nearly 30% of lung adenocarcinomas are driven by an activating KRAS mutation. Oncogenic mutations of the KRAS gene usually occur in exon 2 at codon 12, but they occur less frequently at codon 13 (3%-5% of lung adenocarcinoma cases) and, rarely, at exon 3 codon 61 (less than 1% of cases). Although effective targeted therapies have been elusive, novel and emerging approaches to the management of KRAS-mutated NSCLC offer the hope of improved outcomes.

How much do you know about KRAS mutations in NSCLC? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.